

Ramn Garca-Sanz

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9154013/ramon-garcia-sanz-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

320
papers

16,203
citations

63
h-index

119
g-index

342
ext. papers

18,917
ext. citations

5.3
avg, IF

5.66
L-index

#	Paper	IF	Citations
320	Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. <i>Leukemia</i> , 2003 , 17, 2257-317	10.7	2404
319	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. <i>Leukemia</i> , 2012 , 26, 149-57	10.7	580
318	Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised controlled trial. <i>Lancet Oncology</i> , 2012 , 13, 201-11	21.7	384
317	New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. <i>Blood</i> , 2007 , 110, 2586-92	2.2	365
316	Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. <i>Blood</i> , 2006 , 108, 2165-72	2.2	333
315	EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. <i>Leukemia</i> , 2012 , 26, 2159-71	10.7	308
314	Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. <i>Blood</i> , 2014 , 123, 3073-9	2.2	306
313	Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. <i>Leukemia</i> , 2017 , 31, 2094-2103	10.7	298
312	International prognostic scoring system for Waldenstrom macroglobulinemia. <i>Blood</i> , 2009 , 113, 4163-70	2.2	282
311	International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2347-57	2.2	245
310	Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 Concerted Action BHM4-CT98-3936. <i>Leukemia</i> , 2007 , 21, 201-6	10.7	241
309	Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. <i>Lancet Oncology</i> , 2018 , 19, 370-381	21.7	216
308	Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. <i>Leukemia</i> , 2014 , 28, 384-390	10.7	202
307	Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936. <i>Leukemia</i> , 2007 , 21, 215-21	10.7	195
306	Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia. <i>New England Journal of Medicine</i> , 2018 , 378, 2399-2410	59.2	189
305	Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. <i>Blood</i> , 2008 , 112, 2709-12	2.2	184
304	MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia. <i>Leukemia</i> , 2013 , 27, 1722-8	10.7	179

303	Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases. <i>British Journal of Haematology</i> , 2001 , 115, 575-82	4.5	178
302	Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. <i>British Journal of Haematology</i> , 2013 , 160, 171-6	4.5	173
301	Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. <i>Leukemia</i> , 2010 , 24, 629-37	10.7	173
300	Update on treatment recommendations from the Fourth International Workshop on Waldenström's Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2009 , 27, 120-6	2.2	173
299	The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. <i>Annals of Oncology</i> , 2009 , 20, 1303-17	10.3	171
298	International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. <i>Lancet Oncology</i> , 2019 , 20, e302-e312	21.7	166
297	Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iINNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. <i>Lancet Oncology</i> , 2017 , 18, 241-250	21.7	159
296	C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. <i>Blood</i> , 2014 , 123, 4120-31	2.2	150
295	The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. <i>Leukemia</i> , 2004 , 18, 856-63	10.7	142
294	Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. <i>American Journal of Pathology</i> , 1998 , 152, 1655-65	5.8	137
293	Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). <i>Blood</i> , 2013 , 122, 3276-82	2.2	135
292	International Myeloma Working Group recommendations for global myeloma care. <i>Leukemia</i> , 2014 , 28, 981-92	10.7	132
291	Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. <i>Leukemia</i> , 2014 , 28, 391-7	10.7	129
290	Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. <i>Blood</i> , 2012 , 120, 2581-8	2.2	129
289	Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. <i>Blood</i> , 2016 , 128, 1321-8	2.2	125
288	Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. <i>Blood</i> , 2007 , 110, 3112-21	2.2	123
287	Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. <i>Haematologica</i> , 2005 , 90, 1365-72	6.6	122
286	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 2039-2051	4.7	114

285	BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. <i>Bone Marrow Transplantation</i> , 1997 , 20, 451-8	4.4	113
284	Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value. <i>Blood</i> , 2003 , 101, 4695-700	2.2	112
283	A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. <i>Blood</i> , 2020 , 136, 2038-2050	2.2	110
282	Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. <i>Blood</i> , 2014 , 124, 1404-11	2.2	107
281	The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells. <i>Clinical Cancer Research</i> , 2011 , 17, 1692-700	12.9	100
280	A new staging system for multiple myeloma based on the number of S-phase plasma cells. <i>Blood</i> , 1995 , 85, 448-455	2.2	100
279	Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. <i>Blood</i> , 2013 , 122, 3591-8	2.2	98
278	Update on recommendations for assessing response from the Third International Workshop on Waldenström's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2006 , 6, 380-3		98
277	Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. <i>Haematologica</i> , 2013 , 98, 79-86	6.6	96
276	Bone marrow mesenchymal stem cells from infants with MLL-AF4+ acute leukemia harbor and express the MLL-AF4 fusion gene. <i>Journal of Experimental Medicine</i> , 2009 , 206, 3131-41	16.6	96
275	Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2020 , 38, 784-792	2.2	94
274	Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study. <i>Leukemia</i> , 2019 , 33, 2241-2253	10.7	92
273	Are myeloma patients with renal failure candidates for autologous stem cell transplantation?. <i>The Hematology Journal</i> , 2000 , 1, 28-36		86
272	6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis. <i>British Journal of Haematology</i> , 2007 , 136, 80-6	4.5	85
271	Adult precursor B-ALL with BCR/ABL gene rearrangements displays a unique immunophenotype based on the pattern of CD10, CD34, CD13 and CD38 expression. <i>Leukemia</i> , 2001 , 15, 406-14	10.7	84
270	Risk of progression in smoldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. <i>British Journal of Haematology</i> , 2010 , 148, 110-4	4.5	82
269	SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status. <i>Leukemia</i> , 2012 , 26, 2521-9	10.7	81
268	The flow cytometric pattern of CD34, CD15 and CD13 expression in acute myeloblastic leukemia is highly characteristic of the presence of PML-RARalpha gene rearrangements. <i>Haematologica</i> , 1999 , 84, 405-12	6.6	76

267	Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. <i>Haematologica</i> , 2008 , 93, 560-5	6.6	72
266	Restoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA replication. <i>Haematologica</i> , 2013 , 98, 640-8	6.6	68
265	Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia. <i>Blood</i> , 2009 , 114, 148-52	2.2	68
264	Using quantification of the PML-RARalpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia. <i>Haematologica</i> , 2007 , 92, 315-22	6.6	68
263	Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. <i>British Journal of Haematology</i> , 2002 , 118, 1034-40	4.5	68
262	Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients. Castelano-Leon \bar{e} (Spain) Cooperative Group for the Study of Monoclonal Gammopathies. <i>British Journal of Haematology</i> , 1995 , 90, 106-12	4.5	68
261	The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. <i>Leukemia</i> , 2010 , 24, 1700-12	10.7	66
260	Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. <i>Blood</i> , 2016 , 127, 1896-906	2.2	65
259	Expression of the CD117 antigen (c-Kit) on normal and myelomatous plasma cells. <i>British Journal of Haematology</i> , 1996 , 95, 489-93	4.5	64
258	Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. <i>British Journal of Haematology</i> , 2004 , 127, 159-64	4.5	62
257	Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications. <i>British Journal of Haematology</i> , 1996 , 93, 81-8	4.5	62
256	A new method for the analysis of plasma cell DNA content in multiple myeloma samples using a CD38/propidium iodide double staining technique. <i>Cytometry</i> , 1994 , 17, 332-9		61
255	Central nervous system involvement by Waldenstr \bar{o} m macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study. <i>British Journal of Haematology</i> , 2016 , 172, 709-15	4.5	60
254	Multiparameter flow cytometry for the identification of the Waldenstr \bar{o} m's clone in IgM-MGUS and Waldenstr \bar{o} m's Macroglobulinemia: new criteria for differential diagnosis and risk stratification. <i>Leukemia</i> , 2014 , 28, 166-73	10.7	57
253	Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma. <i>Clinical Cancer Research</i> , 2010 , 16, 3260-9	12.9	56
252	Bisphosphonate-related osteonecrosis: genetic and acquired risk factors. <i>Oral Diseases</i> , 2009 , 15, 382-7	3.5	54
251	Influence of biologic markers on the outcome of Hodgkin's lymphoma: a study by the Spanish Hodgkin's Lymphoma Study Group. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1664-73	2.2	53
250	Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential. <i>Leukemia</i> , 2015 , 29, 1186-94	10.7	52

249	Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma. <i>Blood</i> , 2014 , 124, 1300-3	2.2	52
248	The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis. <i>Blood</i> , 2011 , 117, 3613-6	2.2	52
247	Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance. <i>Blood</i> , 2011 , 118, 4547-53	2.2	52
246	The cellular origin and malignant transformation of Waldenström macroglobulinemia. <i>Blood</i> , 2015 , 125, 2370-80	2.2	51
245	De novo methylation of tumor suppressor gene p16/INK4a is a frequent finding in multiple myeloma patients at diagnosis. <i>Leukemia</i> , 2000 , 14, 183-7	10.7	50
244	The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma. <i>The Hematology Journal</i> , 2002 , 3, 43-8		49
243	Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies. <i>Haematologica</i> , 2014 , 99, 1365-72	6.6	48
242	Molecular characterization of heavy chain immunoglobulin gene rearrangements in Waldenström's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. <i>Haematologica</i> , 2007 , 92, 635-42	6.6	48
241	Patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR/ABL+ leukemias: incidence and underlying genetic abnormalities. <i>Leukemia</i> , 2003 , 17, 1124-9	10.7	48
240	Treatment of multiple myeloma. <i>Haematologica</i> , 1999 , 84, 36-58	6.6	48
239	Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). <i>Annals of Oncology</i> , 2019 , 30, 612-620	10.7	47
238	Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect. <i>British Journal of Haematology</i> , 2002 , 118, 239-42	4.5	47
237	Genetic heterogeneity of BCR/ABL+ adult B-cell precursor acute lymphoblastic leukemia: impact on the clinical, biological and immunophenotypical disease characteristics. <i>Leukemia</i> , 2005 , 19, 713-20	10.7	47
236	Immunophenotype and DNA cell content in multiple myeloma. <i>Best Practice and Research: Clinical Haematology</i> , 1995 , 8, 735-59		47
235	Expression of Bcl-2 by human bone marrow mast cells and its overexpression in mast cell leukemia. <i>American Journal of Hematology</i> , 1999 , 60, 191-5	7.1	46
234	Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS. <i>Leukemia</i> , 2019 , 33, 2254-2265	10.7	45
233	Treatment for patients with newly diagnosed multiple myeloma in 2015. <i>Blood Reviews</i> , 2015 , 29, 387-403	11.1	44
232	High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics. <i>Leukemia Research</i> , 2009 , 33, 1706-9	2.7	44

231	Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RAR alpha isoforms: a study of the PETHEMA group. <i>British Journal of Haematology</i> , 2001 , 114, 99-103	4.5	44
230	Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction: the prognostic impact of achieving molecular response. <i>British Journal of Haematology</i> , 2008 , 142, 766-74	4.5	43
229	Long FLT3 internal tandem duplications and reduced PML-RAR expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients. <i>Haematologica</i> , 2010 , 95, 745-51	6.6	42
228	Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia. <i>British Journal of Haematology</i> , 2016 , 175, 77-86	4.5	41
227	BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. <i>Blood</i> , 2017 , 129, 456-459	2.2	40
226	A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma. <i>Blood</i> , 2010 , 116, e12-7	2.2	39
225	Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients. <i>International Journal of Cancer</i> , 2004 , 112, 884-9	7.5	38
224	A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. <i>Blood</i> , 2020 , 136, 2401-2409	2.2	38
223	Genomic analysis of high-risk smoldering multiple myeloma. <i>Haematologica</i> , 2012 , 97, 1439-43	6.6	37
222	Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma. <i>Leukemia</i> , 2017 , 31, 1446-1449	10.7	35
221	Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. <i>Haematologica</i> , 2014 , 99, 1114-22	6.6	35
220	The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma. <i>Haematologica</i> , 2015 , 100, e53-5	6.6	35
219	Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). <i>Blood Cancer Journal</i> , 2018 , 8, 117	7	35
218	Low frequency of the TEL/AML1 fusion gene in acute lymphoblastic leukaemia in Spain. <i>British Journal of Haematology</i> , 1999 , 107, 667-9	4.5	34
217	Design and application of a 23-gene panel by next-generation sequencing for inherited coagulation bleeding disorders. <i>Haemophilia</i> , 2016 , 22, 590-7	3.3	34
216	BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML). <i>Annals of Hematology</i> , 2010 , 89, 453-8	3	33
215	The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia. <i>Haematologica</i> , 2008 , 93, 1797-805	6.6	33
214	Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. <i>Lancet Oncology</i> , 2021 , 22, e119-e130	21.7	33

213	High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation. <i>Haematologica</i> , 2017 , 102, 160-167	6.6	32
212	Is this the time to introduce minimal residual disease in multiple myeloma clinical practice?. <i>Clinical Cancer Research</i> , 2015 , 21, 2001-8	12.9	32
211	Highly sensitive mutation detection by droplet digital polymerase chain reaction in Waldenström macroglobulinemia. <i>Haematologica</i> , 2018 , 103, 1029-1037	6.6	32
210	Incomplete DJH rearrangements of the IgH gene are frequent in multiple myeloma patients: immunobiological characteristics and clinical implications. <i>Leukemia</i> , 2003 , 17, 1398-403	10.7	31
209	FLT3-activating mutations are associated with poor prognostic features in AML at diagnosis but they are not an independent prognostic factor. <i>The Hematology Journal</i> , 2004 , 5, 239-46		29
208	DNA cell content studies in multiple myeloma. <i>Leukemia and Lymphoma</i> , 1996 , 23, 33-41	1.9	29
207	Upregulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients. <i>Haematologica</i> , 2011 , 96, 468-71	6.6	28
206	Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma. <i>Annals of Hematology</i> , 2010 , 89, 803-11	3	28
205	Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma. <i>Blood</i> , 2021 , 137, 49-60	2.2	28
204	Heteroduplex analysis of VDJ amplified segments from rearranged IgH genes for clonality assessments in B-cell non-Hodgkin's lymphoma. A comparison between different strategies. <i>Haematologica</i> , 1999 , 84, 779-84	6.6	28
203	Application of a molecular diagnostic algorithm for haemophilia A and B using next-generation sequencing of entire F8, F9 and VWF genes. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 66-74	7	27
202	The combination of bortezomib and dexamethasone is an efficient therapy for relapsed/refractory scleromyxedema: a rare disease with new clinical insights. <i>European Journal of Haematology</i> , 2012 , 88, 450-4	3.8	26
201	ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma. <i>Annals of Hematology</i> , 2014 , 93, 1745-53	3	25
200	Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study. <i>British Journal of Haematology</i> , 2013 , 163, 581-9	4.5	25
199	Deletions and rearrangements of cyclin-dependent kinase 4 inhibitor gene p16 are associated with poor prognosis in B cell non-Hodgkin's lymphomas. <i>Leukemia</i> , 1997 , 11, 1915-20	10.7	25
198	Risk of recurrent venous thrombosis in patients with G20210A mutation in the prothrombin gene or factor V Leiden mutation. <i>Blood Coagulation and Fibrinolysis</i> , 2006 , 17, 23-8	1	25
197	p16/INK4a gene inactivation by hypermethylation is associated with aggressive variants of monoclonal gammopathies. <i>The Hematology Journal</i> , 2001 , 2, 146-9		25
196	Molecular characterization of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma: antigen-driven origin and IGHV4-34 as a particular subgroup of the non-GCB subtype. <i>American Journal of Pathology</i> , 2012 , 181, 1879-88	5.8	24

195	Short-term endothelial progenitor cell colonies are composed of monocytes and do not acquire endothelial markers. <i>Cytotherapy</i> , 2007 , 9, 14-22	4.8	24
194	Incomplete DJH rearrangements as a novel tumor target for minimal residual disease quantitation in multiple myeloma using real-time PCR. <i>Leukemia</i> , 2003 , 17, 1051-7	10.7	24
193	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). <i>Journal of Hematology and Oncology</i> , 2021 , 14, 168	22.4	24
192	Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review. <i>Lancet Haematology</i> , 2018 , 5, e299-e309	14.6	24
191	Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length. <i>International Journal of Cancer</i> , 2015 , 136, E351-8	7.5	23
190	Circulating clonotypic B cells in multiple myeloma and monoclonal gammopathy of undetermined significance. <i>Haematologica</i> , 2014 , 99, 155-62	6.6	23
189	Prognostic features of multiple myeloma. <i>Best Practice and Research in Clinical Haematology</i> , 2005 , 18, 569-83	4.2	23
188	Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma. <i>Haematologica</i> , 2017 , 102, 922-931	6.6	22
187	Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines. <i>PLoS ONE</i> , 2014 , 9, e92378	3.7	22
186	Detection of MYD88 L265P mutation by real-time allele-specific oligonucleotide polymerase chain reaction. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2014 , 22, 768-73	1.9	22
185	Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma. <i>British Journal of Haematology</i> , 2008 , 141, 212-5	4.5	22
184	Methylenetetrahydrofolate reductase genotype does not play a role in multiple myeloma pathogenesis. <i>British Journal of Haematology</i> , 2002 , 117, 890-2	4.5	22
183	Insights into epigenetic regulation of microRNA-155 expression in multiple myeloma. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2015 , 1849, 353-66	6	21
182	Brentuximab Vedotin Plus ESHAP (BRESHAP) Is a Highly Effective Combination for Inducing Remission in Refractory and Relapsed Hodgkin Lymphoma Patients Prior to Autologous Stem Cell Transplant: A Trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMC). <i>Blood</i> , 2016 , 128, 1169-1169	2.2	21
181	Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes. <i>Blood</i> , 1998 , 91, 3366-71	2.2	21
180	Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. <i>Blood Advances</i> , 2020 , 4, 6009-6018	7.8	20
179	A new staging system for multiple myeloma based on the number of S-phase plasma cells. <i>Blood</i> , 1995 , 85, 448-55	2.2	20
178	Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma. <i>Blood Cancer Journal</i> , 2020 , 10, 108	7	20

177	Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma. <i>Clinical Cancer Research</i> , 2017 , 23, 6602-6615	12.9	19
176	DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2017 , 10, 92	22.4	19
175	The cryptic IRF2BP2-RARA fusion transforms hematopoietic stem/progenitor cells and induces retinoid-sensitive acute promyelocytic leukemia. <i>Leukemia</i> , 2017 , 31, 747-751	10.7	19
174	Heteroduplex PCR analysis of rearranged immunoglobulin genes for clonality assessment in multiple myeloma. <i>Haematologica</i> , 1999 , 84, 328-35	6.6	19
173	Molecular characteristics and gene segment usage in IGH gene rearrangements in multiple myeloma. <i>Haematologica</i> , 2005 , 90, 906-13	6.6	19
172	Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2016 , 22, 207-17	12.9	18
171	Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma. <i>Leukemia</i> , 2019 , 33, 2324-2330	10.7	18
170	Impact of polymorphic variation at 7p15.3, 3p22.1 and 2p23.3 loci on risk of multiple myeloma. <i>British Journal of Haematology</i> , 2012 , 158, 805-9	4.5	18
169	HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma. <i>Blood</i> , 2013 , 122, 1448-54	2.2	18
168	Two new 3' PML Breakpoints in t(15;17)(q22;q21)-positive acute promyelocytic leukemia 2000 , 27, 35-43		18
167	International Prognostic Scoring System (IPSS) for Waldenstrom's Macroglobulinemia (WM).. <i>Blood</i> , 2006 , 108, 127-127	2.2	18
166	Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array. <i>Hematological Oncology</i> , 2017 , 35, 746-751	1.3	17
165	Immunoglobulin lambda isotype gene rearrangements in B cell malignancies. <i>Leukemia</i> , 2001 , 15, 121-7	10.7	17
164	Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma. <i>Leukemia</i> , 2016 , 30, 2026-2031	10.7	17
163	The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma. <i>Annals of Hematology</i> , 2013 , 92, 97-100	3	16
162	The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy. <i>Leukemia and Lymphoma</i> , 2017 , 58, 1144-1152	1.9	16
161	A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma. <i>Journal of Molecular Diagnostics</i> , 2017 , 19, 99-106	5.1	16
160	Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial. <i>Haematologica</i> , 2015 , 100, 1207-13	6.6	15

159	Genomic evolution of ibrutinib-resistant clones in Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2020 , 189, 1165-1170	4.5	15
158	Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design. <i>PLoS ONE</i> , 2020 , 15, e0227986	3.7	15
157	Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease. <i>Haematologica</i> , 2012 , 97, 616-21	6.6	15
156	Bone remodeling markers are useful in the management of monoclonal gammopathies. <i>The Hematology Journal</i> , 2004 , 5, 480-8		15
155	The detection of contaminating clonal cells in apheresis products is related to response and outcome in multiple myeloma undergoing autologous peripheral blood stem cell transplantation. <i>Leukemia</i> , 2000 , 14, 1493-9	10.7	15
154	The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution. <i>Leukemia</i> , 2015 , 29, 1435-7	10.7	14
153	FAM46C controls antibody production by the polyadenylation of immunoglobulin mRNAs and inhibits cell migration in multiple myeloma. <i>Journal of Cellular and Molecular Medicine</i> , 2020 , 24, 4171-4182	5.6	14
152	A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America. <i>Journal of Medical Economics</i> , 2018 , 21, 525-536	2.4	14
151	High-resolution copy number analysis of paired normal-tumor samples from diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2016 , 95, 253-62	3	14
150	From Waldenström's macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation. <i>Blood Cancer Journal</i> , 2017 , 7, e591	7	14
149	Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?. <i>British Journal of Haematology</i> , 2008 , 140, 324-6	4.5	14
148	Association of CD4+/CD56+/CD57+/CD8+(dim) large granular lymphocytic leukemia, splenic B-cell lymphoma with circulating villous lymphocytes, and idiopathic erythrocytosis. <i>Annals of Hematology</i> , 2001 , 80, 685-90	3	14
147	A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: results from the IMMEnSE consortium and meta-analysis. <i>Oncotarget</i> , 2016 , 7, 59029-59048	3.3	14
146	Kappa deleting element as an alternative molecular target for minimal residual disease assessment by real-time quantitative PCR in patients with multiple myeloma. <i>European Journal of Haematology</i> , 2012 , 89, 328-35	3.8	13
145	Frequency of HLA-A, -B and -DRB1 specificities and haplotypic associations in the population of Castilla y León (northwest-central Spain). <i>Tissue Antigens</i> , 2011 , 78, 249-55		13
144	Novel treatment regimens for Waldenström's macroglobulinemia. <i>Expert Review of Hematology</i> , 2010 , 3, 339-50	2.8	13
143	Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series. <i>Leukemia and Lymphoma</i> , 2012 , 53, 812-9	1.9	13
142	Polymorphisms in xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and multiple myeloma risk: a case-control study in the context of the International Multiple Myeloma rESEarch (IMMEnSE) consortium. <i>Leukemia</i> , 2012 , 26, 1419-22	10.7	13

141	Evaluation of the Regimen Brentuximab Vedotin Plus ESHAP (BRESHAP) in Refractory or Relapsed Hodgkin Lymphoma Patients: Preliminary Results of a Phase I-II Trial from the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO). <i>Blood</i> , 2015 , 126, 582-582	2.2	13
140	Impact of the COVID-19 pandemic on the care of cancer patients in Spain. <i>ESMO Open</i> , 2021 , 6, 100157	6	13
139	WM, MYD88, and CXCR4: following the thread. <i>Blood</i> , 2016 , 128, 746-8	2.2	13
138	Detection of single and associated lesions of the Bcl-1, Bcl-2, Bcl-6, c-myc, p53 and p16 genes in B-cell non-Hodgkin's lymphomas: value of molecular analysis for a better assignment of the histologic subtype. <i>Haematologica</i> , 1998 , 83, 209-16	6.6	13
137	Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy. <i>British Journal of Haematology</i> , 2016 , 174, 859-67	4.5	12
136	Comprehensive investigation of genetic variation in the 8q24 region and multiple myeloma risk in the IMMEnSE consortium. <i>British Journal of Haematology</i> , 2012 , 157, 331-8	4.5	12
135	Post-treatment bone marrow residual disease > 5% by flow cytometry is highly predictive of short progression-free and overall survival in patients with Waldenström's macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011 , 11, 168-71	2	12
134	Functional class switch recombination may occur 'in vivo' in Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2007 , 136, 114-6	4.5	12
133	Thalidomide in combination with cyclophosphamide and dexamethasone (thacydex) is effective in soft-tissue plasmacytomas. <i>British Journal of Haematology</i> , 2002 , 119, 883-4	4.5	12
132	Expression of high amounts of the CD117 molecule in a case of B-cell non-Hodgkin's lymphoma carrying the t(14:18) translocation. <i>American Journal of Hematology</i> , 2000 , 63, 226-9	7.1	12
131	A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data. <i>Blood</i> , 2018 , 132, 1620-1620	2.2	12
130	Ibrutinib Therapy in Rituximab-Refractory Patients with Waldenström's Macroglobulinemia: Initial Results from an International, Multicenter, Open-Label Phase 3 Substudy (iNOVATETM). <i>Blood</i> , 2015 , 126, 2745-2745	2.2	12
129	Multiple Myeloma Minimal Residual Disease. <i>Cancer Treatment and Research</i> , 2016 , 169, 103-122	3.5	12
128	A phase II study to evaluate lenalidomide in combination with metronomic-dose cyclophosphamide in patients with heavily pretreated classical Hodgkin lymphoma. <i>Acta Oncologica</i> , 2015 , 54, 933-8	3.2	11
127	Genetic variants and multiple myeloma risk: IMMEnSE validation of the best reported associations--an extensive replication of the associations from the candidate gene era. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 670-4	4	11
126	Comorbidities, not age, are predictive of survival after autologous hematopoietic cell transplantation for relapsed/refractory Hodgkin's lymphoma in patients older than 50 years. <i>Annals of Hematology</i> , 2017 , 96, 9-16	3	11
125	Multiple myeloma: treatment evolution. <i>Hematology</i> , 2012 , 17 Suppl 1, S3-6	2.2	11
124	Molecular biology of myeloma. <i>Clinical and Translational Oncology</i> , 2007 , 9, 618-24	3.6	11

123	Thalidomide in multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2006 , 7, 195-213	4	11
122	Analysis of methylation pattern in multiple myeloma. <i>Acta Haematologica</i> , 2005 , 114 Suppl 1, 23-6	2.7	11
121	Gene scanning of VDJH-amplified segments is a clinically relevant technique to detect contaminating tumor cells in the apheresis products of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2001 , 28, 665-72	4.4	11
120	Debate round-table: comments concerning chimerism studies. <i>Leukemia</i> , 2001 , 15, 1986-8	10.7	11
119	Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2020 , 135, 2375-2387	2.2	11
118	Evidence of long-term disease control with panobinostat maintenance in patients with relapsed multiple myeloma. <i>Haematologica</i> , 2015 , 100, e289-91	6.6	10
117	Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMENSE consortium. <i>Endocrine-Related Cancer</i> , 2015 , 22, 545-59	5.7	10
116	Primary cutaneous localized amyloid elastosis. <i>American Journal of Dermatopathology</i> , 2010 , 32, 86-90	0.9	10
115	Integrative analysis of DNA copy number, DNA methylation and gene expression in multiple myeloma reveals alterations related to relapse. <i>Oncotarget</i> , 2016 , 7, 80664-80679	3.3	10
114	Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials. <i>PLoS ONE</i> , 2018 , 13, e0203392	3.7	10
113	Potential Survival Benefit for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation after Nivolumab Therapy for Relapse/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1534-1542	4.7	9
112	Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing. <i>Haematologica</i> , 2018 , 103, e544-e548	6.6	9
111	Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival. <i>Annals of Hematology</i> , 2012 , 91, 1887-95	3	9
110	Differential diagnosis of IgM MGUS and WM according to B-lymphoid infiltration by morphology and flow cytometry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011 , 11, 93-5	2	9
109	Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNOVATE Study. <i>Journal of Clinical Oncology</i> , 2021 , JCO2100838	2.3	9
108	Origin of Waldenstrom's macroglobulinaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2016 , 29, 136-147	4.2	9
107	The association of increased p14ARF/p16INK4a and p15INK4a gene expression with proliferative activity and the clinical course of multiple myeloma. <i>Haematologica</i> , 2006 , 91, 1551-4	6.6	9
106	A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility. <i>Haematologica</i> , 2018 , 103, 880-889	6.6	8

105	Relapse of multiple myeloma in extramedullary sites after autologous bone marrow transplantation. <i>European Journal of Haematology</i> , 1996 , 56, 181-3	3.8	8
104	Molecular characterization of complete and incomplete immunoglobulin heavy chain gene rearrangements in hairy cell leukemia. <i>Clinical Lymphoma and Myeloma</i> , 2007 , 7, 573-9		8
103	Pegylated liposomal doxorubicin, melphalan and prednisone therapy for elderly patients with multiple myeloma. <i>Hematological Oncology</i> , 2006 , 24, 205-11	1.3	8
102	An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM). <i>American Journal of Hematology</i> , 2016 , 91, 806-11	7.1	7
101	Genetics and molecular epidemiology of multiple myeloma: the rationale for the IMMENSE consortium (review). <i>International Journal of Oncology</i> , 2012 , 40, 625-38	4.4	7
100	The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma. <i>European Journal of Haematology</i> , 2010 , 84, 266-70	3.8	7
99	Sequential intravenous-oral ciprofloxacin plus amoxicillin/clavulanic acid shortens hospital stay in infected non severe neutropenic patients. <i>Hematology and Cell Therapy</i> , 1997 , 39, 223-7		7
98	Transcriptome analysis reveals significant differences between primary plasma cell leukemia and multiple myeloma even when sharing a similar genetic background. <i>Blood Cancer Journal</i> , 2019 , 9, 90	7	7
97	6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival. <i>British Journal of Haematology</i> , 2021 , 192, 843-852	4.5	7
96	Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study. <i>Blood Advances</i> , 2021 , 5, 725-736	7.8	7
95	Immunoparesis in IgM gammopathies as a useful biomarker to predict disease progression. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017 , 55, 1598-1604	5.9	6
94	Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial. <i>Cancers</i> , 2020 , 12,	6.6	6
93	Identification of relapse-associated gene mutations by next-generation sequencing in low-risk acute myeloid leukaemia patients. <i>British Journal of Haematology</i> , 2020 , 189, 718-730	4.5	6
92	Unraveling the heterogeneity of IgM monoclonal gammopathies: a gene mutational and gene expression study. <i>Annals of Hematology</i> , 2018 , 97, 475-484	3	6
91	Identification of miRSNPs associated with the risk of multiple myeloma. <i>International Journal of Cancer</i> , 2017 , 140, 526-534	7.5	6
90	Monoclonal free light chains can be found in heavy chain diseases. <i>Annals of Clinical Biochemistry</i> , 2010 , 47, 570-2	2.2	6
89	Long-term reversibility of renal dysfunction associated to light chain deposition disease with bortezomib and dexamethasone and high dose therapy and autologous stem cell transplantation. <i>Clinics and Practice</i> , 2011 , 1, e95	2.4	6
88	Immune System Alterations in Multiple Myeloma: Molecular Mechanisms and Therapeutic Strategies to Reverse Immunosuppression. <i>Cancers</i> , 2021 , 13,	6.6	6

87	Kikuchi-Fujimoto disease: a case supporting a role for human herpesvirus 7 involvement in the pathogenesis. <i>Rheumatology International</i> , 2013 , 33, 3065-8	3.6	5
86	Polymorphisms in regulators of xenobiotic transport and metabolism genes PXR and CAR do not affect multiple myeloma risk: a case-control study in the context of the IMMENSE consortium. <i>Journal of Human Genetics</i> , 2013 , 58, 155-9	4.3	5
85	Quantitative PCR: an alternative approach to detect common copy number alterations in multiple myeloma. <i>Annals of Hematology</i> , 2017 , 96, 1699-1705	3	5
84	Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma. <i>British Journal of Haematology</i> , 2013 , 163, 223-34	4.5	5
83	Effect of cumulative etoposide doses on the outcome of autologous peripheral-blood progenitor-cell transplantation for lymphoma. <i>Bone Marrow Transplantation</i> , 2004 , 33, 579-87	4.4	5
82	Incomplete DJH rearrangements. <i>Methods in Molecular Medicine</i> , 2005 , 113, 165-73		5
81	Status of methylation of p16 gene in multiple myeloma: a comparative study of three methods for its detection. <i>Clinical Biochemistry</i> , 2000 , 33, 415-8	3.5	5
80	In vitro autonomous proliferation in ANLL: clinical and biological significance. <i>Leukemia Research</i> , 1995 , 19, 411-6	2.7	5
79	Abordaje de la fibrilaci3n auricular en pacientes con c3ncer activo. Documento de consenso de expertos y recomendaciones. <i>Revista Espanola De Cardiologia</i> , 2019 , 72, 749-759	1.5	5
78	A New Next-Generation Sequencing Strategy for the Simultaneous Analysis of Mutations and Chromosomal Rearrangements at DNA Level in Acute Myeloid Leukemia Patients. <i>Journal of Molecular Diagnostics</i> , 2020 , 22, 60-71	5.1	5
77	Immunoglobulin gene rearrangement IGHV3-48 is a predictive marker of histological transformation into aggressive lymphoma in follicular lymphomas. <i>Blood Cancer Journal</i> , 2019 , 9, 52	7	4
76	Absence of spontaneous response improvement beyond day +100 after autologous stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2017 , 52, 567-569	4.4	4
75	Clinical and prognostic value of discrepancies in microsatellite DNA regions between recipient and donor in human leukocyte antigen-identical allogeneic transplantation setting. <i>Transplantation</i> , 2008 , 86, 983-90	1.8	4
74	Hyperhomocysteinemia is a risk factor of recurrent coronary event in young patients irrespective to the MTHFR C677T polymorphism. <i>Thrombosis Research</i> , 2007 , 119, 691-8	8.2	4
73	Cell cycle analysis of Waldenstrom's macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2005 , 5, 250-2		4
72	Preneoplastic somatic mutations including in lymphoplasmacytic lymphoma.. <i>Science Advances</i> , 2022 , 8, eabl4644	14.3	4
71	Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102321	2.2	4
70	A PETHEMA study of high-dose therapy/stem cell support (HDT), including tandem transplant, in primary refractory multiple myeloma (MM): Identification of two populations with different outcomes. <i>Journal of Clinical Oncology</i> , 2007 , 25, 8021-8021	2.2	4

69	A prognostic index predicting survival in transformed Waldenström macroglobulinemia. <i>Haematologica</i> , 2021 , 106, 2940-2946	6.6	4
68	Current functioning of cardio-oncology units in Spain. <i>Clinical and Translational Oncology</i> , 2020 , 22, 1418-1422	3.1	4
67	Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma. <i>Blood Advances</i> , 2020 , 4, 6023-6033	7.8	4
66	Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients. <i>Blood Cancer Journal</i> , 2020 , 10, 14	7	3
65	The presence of DRB1*01 allele in multiple myeloma patients is associated with an indolent disease. <i>Tissue Antigens</i> , 2008 , 71, 548-51		3
64	Myeloma: update on supportive care strategies. <i>Current Treatment Options in Oncology</i> , 2003 , 4, 247-58	5.4	3
63	A Novel Activating Mutation Of CXCR4 Plays a Crucial Role In Waldenstrom Macroglobulinemia Biology. <i>Blood</i> , 2013 , 122, 272-272	2.2	3
62	Generation of a Large Observational Pan-European Data Platform for Treatment and Outcome Patterns in Patients with Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2015 , 126, 2096-2096	2.2	3
61	A new staging system for multiple myeloma based on the number of S- phase plasma cells. <i>Blood</i> , 1995 , 85, 448-455	2.2	3
60	COVID-19 and CAR-T cells: current challenges and future directions-a report from the EPICOVIDEHA survey by EHA-IDWP. <i>Blood Advances</i> , 2021 ,	7.8	3
59	Time to Move to the Single-Cell Level: Applications of Single-Cell Multi-Omics to Hematological Malignancies and Waldenström's Macroglobulinemia-A Particularly Heterogeneous Lymphoma. <i>Cancers</i> , 2021 , 13,	6.6	3
58	Lymphoma Heterogeneity: Three Different Histological Pictures and One Unique Clone. <i>Case Reports in Hematology</i> , 2016 , 2016, 3947510	0.7	3
57	Genomic analysis of a familial myelodysplasia/acute myeloid leukemia and inherited mutations without a pre-existing platelet disorder. <i>Leukemia and Lymphoma</i> , 2020 , 61, 181-184	1.9	3
56	Two new 3' PML Breakpoints in t(15;17)(q22;q21)-positive acute promyelocytic leukemia 2000 , 27, 35		3
55	Zebularine-induced myeloma cell death is accompanied by decreased c-Myc expression. <i>Cellular Oncology (Dordrecht)</i> , 2020 , 43, 743-750	7.2	2
54	Prognosis and Staging of Multiple Myeloma 2013 , 615-636		2
53	Bence Jones Proteinuria in Smoldering Multiple Myeloma As Predictor Marker of Progression to Symptomatic Multiple Myeloma. <i>Blood</i> , 2014 , 124, 3369-3369	2.2	2
52	Genetic Characterization of Waldenstrom Macroglobulinemia By Next Generation Sequencing: An Analysis of Fourteen Genes in a Series of 61 Patients. <i>Blood</i> , 2015 , 126, 2971-2971	2.2	2

51	Next Generation Flow (NGF) for High Sensitive Detection of Minimal Residual Disease (MRD) in Multiple Myeloma (MM). <i>Blood</i> , 2015 , 126, 367-367	2.2	2
50	Prognostic Impact of Molecular Response Assessed By Next-Generation Sequencing in a Large Cohort of Multiple Myeloma Patients. <i>Blood</i> , 2016 , 128, 3283-3283	2.2	2
49	Safety and Efficacy of Filanesib in Combination with Pomalidomide and Dexamethasone in Refractory MM Patients. Phase Ib/II Pomdefil Clinical Trial Conducted By the Spanish MM Group. <i>Blood</i> , 2016 , 128, 4503-4503	2.2	2
48	HLA specificities are associated with prognosis in IGHV-mutated CLL-like high-count monoclonal B cell lymphocytosis. <i>PLoS ONE</i> , 2017 , 12, e0172978	3.7	2
47	Genetically determined telomere length and multiple myeloma risk and outcome. <i>Blood Cancer Journal</i> , 2021 , 11, 74	7	2
46	A safety profile of medications used to treat Waldenström's macroglobulinemia. <i>Expert Opinion on Drug Safety</i> , 2018 , 17, 609-621	4.1	2
45	Expression of p53 protein isoforms predicts survival in patients with multiple myeloma.. <i>American Journal of Hematology</i> , 2022 ,	7.1	2
44	Capillary electrophoresis single-strand conformation analysis (CE-SSCA) for clonality detection in lymphoproliferative disorders. <i>Journal of Hematopathology</i> , 2012 , 5, 83-89	0.4	1
43	Application of self-quenched JH consensus primers for real-time quantitative PCR of IGH gene to minimal residual disease evaluation in multiple myeloma. <i>Journal of Molecular Diagnostics</i> , 2006 , 8, 364- 70 ⁵¹	5.1	1
42	Booster effect after SARS-CoV-2 vaccination in hematological immunocompromised patients with prior COVID-19.. <i>Blood Advances</i> , 2021 ,	7.8	1
41	VDJH Gene Repertoire Analysis in Multiple Myeloma (MM) Patients: Correlation with Clinical Data. <i>Blood</i> , 2018 , 132, 4446-4446	2.2	1
40	Clinical Efficacy of Bortezomib Based Therapy in Plasma Cell Leukemias.. <i>Blood</i> , 2007 , 110, 2726-2726	2.2	1
39	Library Preparation Is the Major Factor Affecting Differences in Results of Immunoglobulin Gene Rearrangements Detection on Two Major Next-Generation Sequencing Platforms. <i>Blood</i> , 2015 , 126, 1411- 1411 ¹	2.2	1
38	Usefulness of Serum-Free-Light-Chains-Ratio (SFLCR) and Serum Heavy-Light-Chains-Ratio (SHLCR) in Multiple Myeloma in the Context of Three GEM/Pethema Clinical Trials. <i>Blood</i> , 2015 , 126, 2962-2962	2.2	1
37	Bortezomib, Dexamethasone and Rituximab in Newly Diagnosed Patients with Waldenström's Macroglobulinemia: Final Analysis of a Phase 2 Study after a Minimum Follow up of 6 Years. <i>Blood</i> , 2016 , 128, 2957-2957	2.2	1
36	Validation of the EuroClonality-NGS DNA capture panel as an integrated genomic tool for lymphoproliferative disorders. <i>Blood Advances</i> , 2021 , 5, 3188-3198	7.8	1
35	PS1352 DISSECTING THE BONE MARROW IMMUNE MICROENVIRONMENT IN THE COMPLETE SPECTRUM OF MONOCLONAL GAMMOPATHIES: POTENTIAL IMPLICATIONS IN DISEASE PATHOGENESIS. <i>HemaSphere</i> , 2019 , 3, 617-618	0.3	1
34	Post-Transcriptional Modifications Explain the Overexpression of CCND2 in Multiple Myeloma. <i>Blood</i> , 2014 , 124, 2001-2001	2.2	1

33	The Presence of MDS-like Phenotypic Abnormalities (MDS-PA) Identifies Newly Diagnosed Multiple Myeloma (MM) Patients with MDS/AML-Related Somatic Mutations and Inferior Survival. <i>Blood</i> , 2016 , 128, 375-375	2.2	1
32	Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients. <i>International Journal of Cancer</i> , 2021 , 149, 327-336	7.5	1
31	Liquid biopsy: a non-invasive approach for Hodgkin lymphoma genotyping. <i>British Journal of Haematology</i> , 2021 , 195, 542-551	4.5	1
30	Multiple primary cutaneous plasmacytoma a decade after a nasal solitary extramedullary plasmacytoma: a puzzling case. <i>Clinical Case Reports (discontinued)</i> , 2016 , 4, 1096-1100	0.7	1
29	Exportin-1 E571K mutation is a common finding in patients with classical Hodgkin lymphoma. <i>Hematological Oncology</i> , 2019 , 37, 215-218	1.3	1
28	Common gene variants within 3'-untranslated regions as modulators of multiple myeloma risk and survival. <i>International Journal of Cancer</i> , 2021 , 148, 1887-1894	7.5	1
27	Waldenström's Macroglobulinemia: An Exploration into the Pathology and Diagnosis of a Complex B-Cell Malignancy. <i>Journal of Blood Medicine</i> , 2021 , 12, 795-807	2.3	1
26	MYD88 Mutations: Transforming the Landscape of IgM Monoclonal Gammopathies. <i>International Journal of Molecular Sciences</i> , 2022 , 23, 5570	6.3	1
25	Waldenström's Macroglobulinemia Immunophenotype 2017 , 21-34		0
24	Sustained complete remission with single agent rituximab in relapsed follicular lymphoma as transformed disease after unrelated reduced intensity conditioning allogeneic stem cell transplantation. <i>Annals of Hematology</i> , 2011 , 90, 227-9	3	0
23	A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemia.. <i>Leukemia and Lymphoma</i> , 2022 , 1-12	1.9	0
22	Genetic complexity impacts the clinical outcome of follicular lymphoma patients. <i>Blood Cancer Journal</i> , 2021 , 11, 11	7	0
21	Allele and haplotype frequencies of HLA-A, -B, -C, -DRB1, -DQB1 and -DQA1 in Castile and Leon region from North West of Spain. <i>Human Immunology</i> , 2021 , 82, 549-550	2.3	0
20	RNA sequencing identifies novel regulated IRE1-dependent decay targets that affect multiple myeloma survival and proliferation.. <i>Experimental Hematology and Oncology</i> , 2022 , 11, 18	7.8	0
19	A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma.. <i>Blood Cancer Journal</i> , 2022 , 12, 68	7	0
18	Reply to Yanamandra et al. <i>British Journal of Haematology</i> , 2003 , 120, 1096-1096	4.5	
17	Brentuximab Vedotin Plus ESHAP (BRESHAP) Versus ESHAP As Salvage Strategy for Patients with Primary Refractory or Relapsed Classical Hodgkin's Lymphoma. Preliminary Results from the Breselibet Prospective Clinical Trial. <i>Blood</i> , 2021 , 138, 2459-2459	2.2	
16	A strategic reflection for the management and implementation of CAR-T therapy in Spain: an expert consensus paper.. <i>Clinical and Translational Oncology</i> , 2022 , 1	3.6	

- 15 Influence of GST Gene Polimorphisms in the Developement of Liver Sinusoidal Obstructive Syndrome in Patients with Multiple Myeloma Undergoing Hematopoietic Stem Cell Transplantation.. *Blood*, **2006**, 108, 3084-3084 2.2
- 14 Prognostic Factors and Classification in Multiple Myeloma. *Translational Medicine Series*, **2007**, 115-140
- 13 Immunophenotypic Detection of Minimal Residual Disease in Acute Lymphoblastic Leukemia. *Hamatologie Und Bluttransfusion*, **1997**, 321-327
- 12 A randomized, double-blind, multinational trial comparing denosumab with zoledronic acid for treatment of bone disease in adults with newly diagnosed multiple myeloma.. *Journal of Clinical Oncology*, **2014**, 32, TPS8628-TPS8628 2.2
- 11 Type 2 Diabetes-Related Variants Influence on the Risk of Developing Multiple Myeloma: Results from the Immense Consortium. *Blood*, **2014**, 124, 2044-2044 2.2
- 10 Intraclonal Heterogeneity Associates with Clonal Stability in Multiple Myeloma. *Blood*, **2014**, 124, 3412-3412
- 9 The International Multiple Myeloma Research (IMMENSE) Consortium: Genetics of Multiple Myeloma Risk and Prognosis. *Blood*, **2014**, 124, 3421-3421 2.2
- 8 Simplified in-House Deep Sequencing Method of Immunoglobulin Genes for Minimal Residual Disease Quantification and Risk Stratification in Multiple Myeloma. *Blood*, **2015**, 126, 2972-2972 2.2
- 7 Ultra-Deep Targeted Sequencing Does Not Identify MM Patients with Different Prognosis: Results from a Randomized Phase II Clinical Trial. *Blood*, **2016**, 128, 2078-2078 2.2
- 6 Genomic Comparison Of Clonal B-Cells In Waldenstrom Macroglobulinemia (WM) Versus IgM MGUS. *Blood*, **2013**, 122, 400-400 2.2
- 5 Phenotypic, Transcriptomic and Genomic Characterization Of Clonal Plasma Cells (PCs) From Newly Diagnosed Patients With Light Chain Amyloidosis (AL). *Blood*, **2013**, 122, 1841-1841 2.2
- 4 Phenotypic and Genomic Analysis Of Multiple Myeloma (MM) Minimal Residual Disease (MRD) Clonal Plasma Cells (PCs). *Blood*, **2013**, 122, 402-402 2.2
- 3 Reply to Brown et'al: 'Correct application of variant classification guidelines in germline mutated disorders to assist clinical diagnosis'. *Leukemia and Lymphoma*, **2020**, 61, 248-249 1.9
- 2 Primary amyloidosis. *Medicina Clínica (English Edition)*, **2016**, 147, 121-126 0.3
- 1 Management of mixed acute rejection driven by a donor-specific complement-binding anti-DQB1*03:01 antibody and intraepithelial CD8 T-cells in a kidney recipient: a case report. *British Journal of Biomedical Science*, **2021**, 78, 244-247 1.6